Mazumdar-Shaw on Biocon’s Mission to Make Life-Saving Drugs Accessible

Watch on YouTube ↗  |  August 21, 2026 at 00:06  |  24:01  |  Bloomberg Markets
Speakers
Kiran Mazumdar Shaw — Founder & Chairperson, Biocon

Summary

Kiran Mazumdar-Shaw discusses Biocon's high-volume, affordability-driven biopharma model, its biosimilars and insulin leadership, and its positioning in generic GLP-1s. She argues Biocon can gain insulin share as rivals shift capacity to GLP-1s and that its fermentation-based portfolio avoids Chinese API dependence. The conversation also covers India's push for biotech sovereignty in AI, supply-chain resilience, succession, and legacy.

  • Biocon was built on a high-volume, low-price model to expand patient access.
  • Insulin is viewed as a windfall opportunity as competitors prioritize GLP-1s.
  • Generic GLP-1s are described as crowded, with Biocon expecting a small but good share.
  • Biocon's fermentation and biologics portfolio avoids reliance on Chinese APIs.
  • India is positioned as a potential biotech/AI equal partner with strategic opportunity.
  • Biocon's integrated Bengaluru campus supports global-scale competitive manufacturing.
  • Succession plans see niece Claire in a strategic board role.
Ideas
Kiran Mazumdar Shaw Founder & Chairperson, Biocon 2:22
Biocon wins via high-volume affordable medicines.
Biocon was built on a high-volume, low-price model to serve more patients rather than restricting life-saving drugs to those who can afford high prices; profits are driven by volume and affordability, disrupting the Western low-volume, high-value pharmaceutical model.
BIOCON HIGH
Kiran Mazumdar Shaw Founder & Chairperson, Biocon 7:58
India can become biotech AI equal partner.
India should embed biotech sovereignty in AI by owning its biological data and knowledge so it can trade as an equal partner; India has the talent, developing infrastructure and strategic opportunity to be among the handful of countries between the US and China in biotech/AI.
INDA MED
Up Next
1:26
Mazumdar-Shaw’s Mission to Expand Access to Vital Drugs
Bloomberg Markets · Aug 21
44:19
Mad Money 08/20/26 | Audio Only
CNBC · Aug 20
1:42
There is no AI without memory, says Micron CEO Mehrotra
CNBC · Aug 20
21:04
Taste is the new programming language (w/ Astrocade CEO Amir Sadeghian) | AI Basics
This Week in Startups · Aug 20
51:23
Trump Threatens ‘Economic D-Day’ Against Iran | Balance of Power 08/20/2026
Bloomberg Markets · Aug 20

This Bloomberg Markets video, published August 21, 2026, features Kiran Mazumdar Shaw discussing BIOCON, INDA. 2 trade ideas extracted by AI with direction and confidence scoring.

Speakers: Kiran Mazumdar Shaw  · Tickers: BIOCON, INDA